CCL17 Chemokine Detection Tools: One-Step Human CCL17 ELISA Kit for Autoimmunity & Tumor Immunity Basic Research

Core Biological Function of CCL17 Chemokine in Immune Signaling Cascades

CCL17, also termed thymus and activation-regulated chemokine (TARC), belongs to the CC-type chemokine superfamily with specialized chemotactic activity toward CCR4-expressing immune cell subsets. CCR4 receptors are predominantly expressed on regulatory T cells (Treg), Th2 helper lymphocytes and tissue-resident myeloid populations, rendering CCL17 a master immune chemotactic signal. Under inflammatory stimulation, epidermal keratinocytes, dendritic cells and tumor stromal fibroblasts secrete abundant soluble CCL17 into tissue interstitial fluid and peripheral circulation. Elevated CCL1 concentration reshapes local immune microenvironments by recruiting immunosuppressive Treg populations to lesion sites, while amplifying Th2-type inflammatory cytokine secretion in autoimmune tissue models. Dual functional roles link CCL1 to both chronic inflammatory skin disorders and solid tumor immune escape phenotypes, making quantitative CCL1 measurement a core readout for immunological mechanism research.

Research Background: Dual Pathological Roles of CCL1 Across Autoimmunity and Tumor Models

Two major preclinical research branches systematically characterize CCL1-mediated immune regulatory circuits. In psoriasis preclinical models, sustained CCL1 secretion synergizes with IL-17A and IL-23 inflammatory axes to drive hyperproliferative keratinocyte phenotypes and continuous pro-inflammatory cytokine release. Combined neutralization targeting CCL1 and IL-17A generates additive inhibitory effects on epidermal overgrowth and tissue inflammatory infiltration compared to single-agent treatment groups. Within gastrointestinal and hepatic tumor microenvironments, stromal-derived CCL1 recruits circulating Treg cells to malignant lesions, blunting endogenous CD8+ cytotoxic T cell anti-tumor effector activity. Co-administration of anti-CCL1 reagents alongside PD-1/PD-L1 checkpoint antibodies reinvigorates intratumoral lymphocyte infiltration and suppresses xenograft tumor proliferation in murine liver and gastric carcinoma models. CCL1 also participates in organ fibrotic remodeling by coordinating TGF-β downstream extracellular matrix deposition signaling networks.

Conventional CCL1 Quantification Technical Limitations

Traditional sandwich ELISA workflows for CCL1 detection require multiple sequential incubation and repeated wash steps, extending total assay handling durations and elevating human operation error risks. Standard two-step ELISA protocols separate capture antibody coating, sample incubation and secondary antibody binding into discrete stages, demanding extended bench time for high-throughput cohort screening. Low baseline assay sensitivity limits reliable measurement of low picogram-range CCL concentrations within diluted cell culture supernatants and plasma biospecimens. Many commercial CCL ELISA kits exhibit non-specific matrix interference in serum or tumor homogenate samples, generating inconsistent absorbance readouts across parallel experimental replicates. These technical constraints create consistent experimental bottlenecks for large-scale autoimmune and tumor immune preclinical screening pipelines.

Core Advantages of One-Step CCL1 ELISA Detection Format

ANT BIO PTE. LTD. one-step Human CCL1 ELISA Kit reconfigures traditional multi-stage immunoassays into unified single incubation and single washing operation workflows. Capture and detection antibody conjugates are pre-formulated within the working buffer system, eliminating separate secondary antibody incubation steps to cut total assay operation time significantly. Optimized antigen-antibody reaction buffer minimizes plasma and tissue homogenate matrix interference to stabilize optical density readouts across sample dilution gradients. The kit achieves a minimum detectable concentration of 4.883 pg/mL, enabling precise quantification of trace CCL1 levels from dilute culture supernatant and peripheral liquid biospecimens. Uniform pre-coated 96-well plates deliver consistent well-to-well signal uniformity to reduce replicate coefficient of variation for longitudinal immune cohort comparative analysis.

Multi-Pathway Co-Treatment Research Applications for CCL1 Quantification

Quantitative CCL1 measurement via this one-step ELISA kit supports three major combinatorial intervention research pipelines. Psoriasis autoimmunity co-culture assays measure CCL1 abundance after IL-17A/IL-23 inhibitor single or combined compound incubation to evaluate synergistic anti-inflammatory potency. Tumor immunotherapy screening quantifies soluble CCL1 shifts post anti-CCL1 and PD-L1 antibody co-treatment to assess Treg recruitment suppression and restored cytotoxic T cell activity. Fibrosis mechanism research monitors CCL1 concentration dynamics under TGF-β pathway antagonist intervention to dissect chemokine-mediated extracellular matrix remodeling cascades. Time-course supernatant sampling from activated dendritic and fibroblast cell lines tracks CCL1 secretory kinetics under inflammatory cytokine stimulation cycles.

Standardized Assay Operation Workflow of S0C3072 One-Step CCL1 ELISA Kit

The streamlined single-step protocol eliminates repeated liquid transfer steps to streamline high-throughput sample processing. Thawed test samples and serial CCL1 standard dilutions are directly mixed with pre-mixed one-step antibody working solution and loaded onto pre-coated microplate wells simultaneously. The unified incubation reaction proceeds under controlled temperature conditions without intermediate washing intervals. A single plate washing cycle removes unbound matrix proteins and excess detection reagents prior to TMB chromogenic substrate addition. Stop solution terminates color development, and microplate absorbance at 450 nm wavelength is recorded via standard microplate readers for standard curve-based absolute CCL1 concentration calculation. Complete operation reduces manual handling steps compared to conventional two-step ELISA platforms.

Fundamental Research Scenarios Supported by ANT BIO PTE. LTD. CCL1 ELISA Kit

Autoimmune dermatology research utilizes S0C3072 to quantify CCL1 secretion from stimulated primary human keratinocytes for anti-inflammatory compound potency ranking. Hepatocellular and gastric tumor xenograft model plasma and tissue supernatant CCL profiling evaluates chemokine-driven immune escape after checkpoint combinatorial therapy. Fibrosis mechanism cell culture assays measure CCL1 release from activated hepatic and cardiac fibroblasts following TGF-β stimulation cycles. Dendritic cell maturation co-culture experiments track CCL1 secretory shifts post TLR agonist treatment to map innate-adaptive immune crosstalk gradients. Serial supernatant collection from long-term immune cell co-cultures enables dynamic CCL secretion kinetic quantification across multi-day stimulation time series.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.